Afoxolaner API is an important veterinary active pharmaceutical ingredient used globally for flea and tick control in dogs. As one of the leading afoxolaner API manufacturers, this article from Qingmu Pharmaceutical covers what afoxolaner is, its mechanism of action, applications in popular veterinary products, manufacturing considerations and an overview of some trusted afoxolaner suppliers.
What is Afoxolaner API?
Afoxolaner API, also known by its brand name NexGard, is a synthetic molecule used as the key active ingredient in oral formulations for flea and tick protection in canines. Its chemical name is 4-[(5R)-5-[3-chloro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4H-1,2-oxazol-3-yl]-N-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]naphthalene-1-carboxamide.
With the molecular formula C26H17ClF9N3O3 and molecular weight of 625.87 g/mol, afoxolaner API belongs to the isoxazoline class of parasiticides. It is a white to off-white powder freely soluble in methanol and exhibits polymorphism under different processing and storage conditions.
How does Afoxolaner API work?
After oral ingestion, afoxolaner API gets rapidly absorbed and distributed systemically in dogs. When an infested flea or tick bites the dog later and ingests afoxolaner API via its blood meal, it blocks the insect's γ-aminobutyric acid (GABA)-gated chloride channels.
Specifically, afoxolaner API acts as an antagonist at these ligand-gated chloride channels. It binds to a unique target site within the insect's central nervous system and prevents the pre- and postsynaptic transfer of chloride ions. This results in uncontrolled neuronal activity and ultimately death of fleas and ticks.
Applications of Afoxolaner API in Veterinary Products
Some of the most popular brands that contain afoxolaner API as the active ingredient include NexGard (for dogs), Frontline (dogs and cats), and NexGard Spectra (dogs).
These are used extensively by veterinarians and pet owners worldwide as orally administered monthly chewables or topically applied spot-ons for eliminating both fleas and ticks in canines. afoxolaner API based products offer excellent efficacy, safety and convenience.
Manufacturing Afoxolaner API
As a key afoxolaner API manufacturer, Qingmu Pharmaceutical produces this valuable veterinary active ingredient using proprietary multi-step synthesis routes. Strict quality controls are applied during each manufacturing stage to consistently deliver API of ≥98% purity.
Advanced analytical techniques such as HPLC, GC-MS, particle size analysis etc. are employed for in-process and final testing. Sophisticated RD also helps optimize yields, crystal polymorphs and scale-up processes.
Qingmu’s facilities meet rigorous ICH, FDA, EU GMP standards with certifications on quality, environment and occupational health safety management.
Sources for Afoxolaner API
Some of the trusted global afoxolaner API suppliers with strong manufacturing/supply track records include:
- Qingmu Pharmaceutical (China)
- Zhejiang Kangmu Bio-Medical Co., Ltd. (China)
- Allis Chemical (India)
- Baisheng Bio-Technology (China)
These established companies have capabilities to consistently deliver commercial volumes of high-quality afoxolaner API to veterinary drug formulations manufacturers worldwide.
Summary
As a frontline treatment against fleas and ticks, afoxolaner API plays a vital role in parasite control and animal healthcare. This article provided a overview of this important veterinary API - from its mechanism and applications to considerations in manufacturing and sourcing from reputed suppliers like Qingmu Pharmaceutical.
